Several PI3K, Akt, and mTOR inhibitors have entered preclinical and clinical stages in treating colorectal cancer by achieving cell cycle arrest, cell apoptosis and elimination of cell survival signals [39,40,41]. This evidence concerns the gene MTOR and colorectal cancer.